B-cell lymphoma gene (BCL-6) upregulation contributes to immortalization of mouse embryo fibroblast and primary B cells via upregulation of cyclin D 1 . As cyclin D 1 overexpression is a common phenomenon in different cancers, BCL-6 protein overexpression may not be restricted to lymphomas. In this study, expression of BCL-6 was investigated by immunohistochemistry on paraffin-embedded specimens from 150 breast cancer patients and 10 specimens of normal breast tissue. The results showed BCL-6 overexpression (X10% of cells) in 24/150 (16%) breast cancer patients, whereas in normal breast low expression (o1%) of BCL-6 was observed. In linear regression analysis BCL-6 expression was associated with cyclin D 1 (r ¼ 0.197, P ¼ 0.016). Further, in v 2 analyses, BCL-6-positivity was associated with overexpression of p53 (P ¼ 0.016), and hypoxia-inducible factor-1a (Po0.001). Involvement of BCL-6 in breast carcinogenesis is further underscored by comparative genomic hybridization analysis that showed gains at the BCL-6 locus (3q27) in 14/86 (16%) breast cancer tissues. The cases with amplification in BCL-6 showed an increased (25%) incidence of BCL-6 protein overexpression. Thus, this study is the first to show that BCL-6 oncogene activation plays a role in cancers other than lymphomas.
Introduction
The proto-oncogene B-cell lymphoma gene 6 (BCL-6) is located on 3q27, which is the third most common translocated region in non-Hodgkin lymphoma (NHL). The BCL-6 gene encodes a protein that harbors transcriptional repressor activity (Chang et al., 1996) .
Genes carrying its recognition site in the promotor region include many lymphocyte activation genes such as MIP-1a and IP-10 and Blimp-1, and cyclin D 2 (Shaffer et al., 2000) . As yet, not all target genes of BCL-6 have been identified and its real impact and function is still not clarified. BCL-6 is believed to be involved in germinal center B-cell function and the immune response (Ye et al., 1997) . Deregulation of BCL-6 seemed to be uniquely associated with lymphomagenesis, especially for non-Hodgkin B-cell lymphomas such as the diffuse large cell, follicular and marginal zone subtypes (Ye, 2000) , with overexpression levels up to 90% (Dunphy et al., 2001) . Recently, we reported the involvement of BCL-6 in mouse embryonic fibroblast senescence via upregulation of cyclin D 1 (Shvarts et al., 2002) , indicating a more general role for BCL-6 in oncogenesis. Cyclin D 1 is frequently expressed in invasive breast cancer (van Diest et al., 1997) , partly explained by amplification and estrogen receptor a (ERa) activation, but the mechanism is not clear in all cases. BCL-6 could be involved here.
Therefore, we investigated if BCL-6 is expressed in invasive breast cancer and whether this is associated with expression of cyclin D 1 and other biomarkers. We analysed protein levels of BCL-6 by immunohistochemistry in 150 breast cancers previously characterized for expression of the hypoxia-inducible factor-1a (HIF-1a), cyclin D 1 and other common clinicopathologic features (Bos et al., 2003) .
BCL-6 immunohistochemistry
In normal breast tissue (n ¼ 10), weak nuclear staining (o1% of cells) of BCL-6 was noted in glandular epithelial cells. In 53/150 (35%) cases of invasive breast cancer, BCL-6 nuclear expression (X1%) was noted (mean 14%, range 1-75%). BCL-6 overexpression (X10%) was found in 24/150 (16%) breast cancers. Nuclear expression of BCL-6 was sometimes seen in adjacent morphologically normal breast, ductal hyperplasia of usual type and ductal carcinoma in situ (DCIS). A few cases showed nuclear expression of BCL-6 in DCIS but not in the invasive tumor. The staining pattern of BCL-6 varied between scattered, diffuse ( Figure 1a ) and in two cases around necrotic tumor areas (Figure 1b) .
Thus, the dogma that BCL-6 overexpression is a unique feature of lymphomas should be discarded now that BCL-6 protein expression has been noticed in invasive breast cancer. Increased BCL-6 nuclear expression was seen in 35% of invasive breast cancers and BCL-6 protein overexpression was found in 16% of cases. Also, the recognized breast cancer precursor lesions ductal hyperplasia and DCIS showed increased expression sometimes. The expression was largely nuclear where the protein is functionally active, but in two tissues a strong diffuse cytoplasmic staining was seen, which could point to truncated forms or splice variants, sequestered in the cytoplasm.
CGH: 3q27 gains and protein levels of BCL-6
For determining a genetic basis of BCL-6 overexpression, we investigated 3q27 gains in 86 breast cancers by comparative genomic hybridization (CGH). in a separate patient group, in part (n ¼ 53) described before (Hermsen et al., 1998) . In 14/86 (16%) patients, a gain of 3q27, the BCL-6 locus was found. Paraffin blocks were available for 12 of these 14 patients. BCL-6 immunohistochemistry on these cases revealed that 3/12 (25%) had overexpression (X10%) of BCL-6, another three cases showed 5% of BCL-6 expression, two cases showed diffuse strong cytoplasmic expression, while in four of 12 (33%) cases no BCL-6 protein could be detected (Table 1 ). In our reference group of 150 breast cancers, 97 cases were completely BCL-6 negative (P ¼ 0.03, w 2 test) ( Table 1) . Four of the 14 cases with a gain of 3q27 (28%) had an amplification of 11q13 (locus of cyclin D 1 ), while gain at 11q13 was seen in 24/86 (28%) of the reference group (P ¼ 0.950).
Genetic alterations are the main reason for the tumor biological activity of BCL-6 in lymphomas. The data from this study imply that BCL-6 gene amplification could be responsible for protein overexpression in these cases, since the CGH data of 86 breast cancers revealed a gain at the locus of BCL-6 (3q27) in 16% of cases, of which 25% had BCL-6 overexpression at the protein level. However, 33% of the 3q27-positive cases showed no BCL-6 protein expression at all, which might be explained by promoter methylation, or post-transcriptional regulation of the gene. On the other hand, the gain may be due to amplification of another gene located at 3q27.
Immunohistochemistry: association of BCL-6 with other markers
As shown in Table 2 , BCL-6 nuclear overexpression was significantly associated with overexpression of HIF-1a Figure 1 Invasive ductal breast cancer showing diffuse (a) and perinecrotic (b) nuclear BCL-6 immunohistochemical staining (microscope magnification Â 20). After deparaffination and rehydration, antigen retrieval for BCL-6 was performed in an autoclave (1201C, 20 min) with 4 mm thick slides placed in a citrate buffer (pH 6). A mouse monoclonal antibody against BCL-6 (1 : 25, clone PG-B6P, DAKO, Glostrup, Denmark) was incubated 60 min at room temperature. The primary antibody was detected using a biotinylated rabbit anti-mouse antibody (DAKO). This signal was amplified by avidin-biotin complex formation and developed with diaminobenzidine. Appropriate negative (obtained by omission of the primary antibody) and positive controls (normal tonsil with germinal centers) were used throughout. The percentage of tumor cells harboring nuclear BCL-6 expression was estimated in each case by one pathologist (PvD), who was blinded to any outcome. Staining and scoring protocols for the other biomarkers have been described elsewhere (Bos et al., 2003) a This separate group of 86 patients has in part (n ¼ 53) been described before (Hermsen et al., 1998) , and was diagnosed between 1993 and 1998 at the Department of Pathology of VUMC (n ¼ 43) and the Medical Centre Alkmaar (Alkmaar, The Netherlands) (n ¼ 43). These tumors had a mean size of 1.9 cm (range 0.5-6.5), and mean age at the time of diagnosis was 53, ranging from 28 to 84. b Comparative genomic hybridization (CGH) was performed as described before (Hermsen et al., 1998) on DNA extracted from frozen tumor tissue with the QiAmp Tissue Kit (Qiagen GmbH, Hilden, Germany). Results of tumor to normal fluorescence ratios with 95% confidence intervals were plotted in relative copy number karyotypes BCL-6 expression in breast cancer R Bos et al (Po0.001). HIF-1 is a transcription factor consisting of two protein subunits, HIF-1a and HIF-b. While HIF-1b is constitutively present, HIF-1a is under normoxia continuously degraded by the proteasome via ubiquitination by the von Hippel-Lindau tumor suppressor E3 ligase complex (Jaakkola et al., 2001) . During hypoxia, ubiquitination of HIF-1a is blocked and HIF-1a becomes overexpressed, leading to the formation of the active HIF-1 complex in the nucleus. As a survival response, HIF-1 activates several target genes involved in angiogenesis, and glucose/iron metabolism such as vascular endothelial growth factor, glucose transporter1, erythropoietin, transferrin and insulin growth factor-2 (Semenza, 2002) . Recently, several other mechanisms of activating HIF-1 have been defined such as the tumor suppressor genes p53, pVHL and PTEN, oncogenes as HER-2/neu, and growth factors such as insulin-like growth factor-1 (Semenza, 2002) . Hereby, a more direct role of HIF-1 in oncogenesis is postulated. This potential role of HIF-1 in cancer is elucidated by the presence of HIF-1a in different types of solid tumors (Zhong et al., 1999) , increased levels of HIF-1a during breast carcinogenesis (Bos et al., 2001 ) and high levels predicting poor prognosis in lymph node-negative breast cancer (Bos et al., 2003) . In this study, BCL-6 and HIF1a overexpression were found to be positively correlated. As yet, the question arises whether BCL-6 is the next oncogene with HIF-1 activating capacity. BCL-6 bypasses the senescence response in mouse embryonic fibroblasts and primary B cells by ignoring p53 and causing sequestration of p21 by cyclin D 1 (Shvarts et al., 2002) . As HIF-1a is strongly associated with p21 expression (Carmeliet et al., 1998) , this might explain the relation between HIF-1 and BCL-6 reported in the present study. Growth inhibitory signals from hypoxia via the HIF-1 pathway would be counteracted by the presence of BCL-6 and BCL-6-regulated genes. The presence of high levels of p21 would thereby reflect the initial response of the cells to stress from hypoxia.
The current finding that HIF-1a is associated with BCL-6 raises the question as to how HIF-1, as a transcription factor, and BCL-6, as a transcription repressor, are related to each other. This is not unique for breast cancer, as we have also observed concerted overexpression of HIF-1a and BCL-6 in diffuse largecell B-cell lymphomas (unpublished results). No hypoxia response element has been reported in the transcriptional region of BCL-6. One possible explanation could be the repression of VHL by BCL-6. VHL degrades the HIF-1a protein by making it eligible for ubiquitination. Loss of VHL has already been associated with high levels of cyclin D 1 (Bindra et al., 2002) . Downregulation of VHL by BCL-6 would lead to higher levels of HIF1a. However, to date we have no direct data to support this hypothesis. On the other hand, we also occasionally noticed BCL-6 expression in perinecrotic areas as for HIF-1a staining, implying that BCL-6 may be induced by hypoxia. Further research is definitely required to test these assumptions and hypotheses.
BCL-6 nuclear overexpression was also significantly associated with p53 overexpression (P ¼ 0.016). This finding might be due to the general genetic instability caused by p53 mutations, which might give rise to genetic alterations in the BCL-6 gene. A trend was found with cyclin D 1 (P ¼ 0.095), whereas other markers (Table 2) did not show a relationship with BCL-6. As described previously (Bos et al., 2003) , a representative group of 150 breast cancer patients, diagnosed between 1985 and 1993 at the VU University Medical Center, Amsterdam, The Netherlands, was randomly selected. All patients underwent either breast conserving therapy or modified radical mastectomy. For all patients, axillary dissection including at least levels I and II was performed. Histological classification was performed using the WHO criteria. Tumors were graded following the criteria of Elston and Ellis (1991). The mitotic activity index (MAI) was assessed according to an established reproducible protocol (van Diest et al., 1992) . None of the patients received preoperative chemo-, hormonal or radiotherapy. Nonparametric w 2 and Mann-Whitney test (SPSS for Windows Version 9.0.1, 1999, SPSS Inc., Chicago, IL, USA) were used to evaluate correlations. Traditional cutoff values for the other biomarkers were used. For BCL-6, a cut off value of 10% for high BCL-6 protein expression was chosen based on Ree et al. (2003) Linear regression analysis showed that HIF-1a (r ¼ 0.225, P ¼ 0.006) and cyclin D 1 (r ¼ 0.197, P ¼ 0.016), but not p53, p21, MAI or tumor size, were associated with BCL-6 expression (Table 3 ). In addition, a strong positive association between overexpression of both p21 and cyclin D 1 (Po0.001) was found in w 2 analysis (data not shown), confirming our previous results (de Jong et al., 1999) .
In concordance with the potential of BCL-6 to immortalize mouse embryonic fibroblasts by activating cyclin D 1 (Shvarts et al., 2002) , this study shows that BCL-6 and cyclin D 1 overexpression are associated in breast cancer. This finding might be important since many investigators have searched for the cause of cyclin D 1 upregulation in breast cancer, which is a common phenomenon which is just partly explained by a genetic alteration (amplification, translocation) involving the cyclin D 1 gene at locus 11q13 (van Diest et al., 1997) . BCL-6 therefore seems to qualify as a next upregulator of cyclin D 1 . We found no correlation between 3q27 and 11q13 gains in the present study, suggesting that there is no direct causal relationship between these genetic events in breast cancer.
In conclusion, the BCL-6 locus is amplified and the BCL-6 protein is overexpressed in 16% of invasive breast cancers and is related to cyclin D 1 , p53 and HIF1a overexpression. This is the first example of overexpression of BCL-6 in other malignancies than lymphomas. Further research is necessary to investigate the potential carcinogenetic role of BCL-6 in breast cancer and other solid malignancies, and the potential therapeutic implications of these new findings. 
